Search

Your search keyword '"René Olivier"' showing total 990 results
Start Over Author "René Olivier"

Refine your results

more »

more »

more »

more »
990 results on '"René Olivier"'

1. Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab

Author

Cyrielle Rodier, Lukshe Kanagaratnam, David Morland, Adélie Herbin, Amandine Durand, Adrien Chauchet, Sylvain Choquet, Philippe Colin, René Olivier Casasnovas, Eric Deconinck, François Godard, Alain Delmer, Cédric Rossi, and Eric Durot

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Patients (pts) with asymptomatic low-burden follicular lymphoma (FL) are usually observed at diagnosis. Time to lymphoma treatment (TLT) initiation can however be very heterogeneous and risk factors of progression are poorly studied. Our study evaluated 201 pts with grade 1–3a low-tumor burden FL diagnosed in four French centers between 2010 and 2020 and managed by a watch and wait strategy in real-life settings. After a median follow-up of 4.8 years, the median TLT was 4.2 years (95% confidence interval, 3.1-5.5). On multivariate analysis, elevated lactate dehydrogenase (hazard ratio [HR] = 2.2; P = 0.02), more than 4 nodal areas involved (HR = 1.7; P = 0.02) and more than 1 extranodal involvement (HR = 2.7; P = 0.01) were identified as independent predictors of TLT. The median TLT was 5.8 years for pts with no risk factor, 2.4 years for 1 risk factor, and 1.3 years for >1 risk factors (P < 0.01). In a subanalysis of 75 pts staged with positron emission tomography-computed tomography (PET-CT), total metabolic tumor volume (TMTV) ≥14 cm3 and standardized Dmax (reflecting tumor dissemination) >0.32 m−1 were also associated with shorter TLT (HR = 3.4; P = 0.004 and HR = 2.4; P = 0.007, respectively). In multivariate models combining PET-CT parameters and clinical variables, TMTV remained independent predictor of shorter TLT. These simple parameters could help to identify FL patients initially observed at higher risk of early progression. The role of PET-CT (extranodal sites and PET metrics) in low-burden FL appears promising and warrants further assessment in large cohorts.

Published
2023
Full Text
View/download PDF

2. Graph-based multimodal multi-lesion DLBCL treatment response prediction from PET images

Author

Thiery, Oriane, Rizkallah, Mira, Bailly, Clément, Bodet-Milin, Caroline, Itti, Emmanuel, Casasnovas, René-Olivier, Gouill, Steven Le, Carlier, Thomas, and Mateus, Diana

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Artificial Intelligence, Electrical Engineering and Systems Science - Signal Processing
Abstract

Diffuse Large B-cell Lymphoma (DLBCL) is a lymphatic cancer involving one or more lymph nodes and extranodal sites. Its diagnostic and follow-up rely on Positron Emission Tomography (PET) and Computed Tomography (CT). After diagnosis, the number of nonresponding patients to standard front-line therapy remains significant (30-40%). This work aims to develop a computer-aided approach to identify high-risk patients requiring adapted treatment by efficiently exploiting all the information available for each patient, including both clinical and image data. We propose a method based on recent graph neural networks that combine imaging information from multiple lesions, and a cross-attention module to integrate different data modalities efficiently. The model is trained and evaluated on a private prospective multicentric dataset of 583 patients. Experimental results show that our proposed method outperforms classical supervised methods based on either clinical, imaging or both clinical and imaging data for the 2-year progression-free survival (PFS) classification accuracy.

Published
2023

3. Herpes Viral Origin of the Parsonage-Turner Syndrome: Highlighting of Serological Immune Anti-Herpes Deficiency Cured by Anti-Herpes Therapy

Author

Jacqueline Le Goaster, Patrice Bourée, Charles Ifergan, Frederic Tangy, René Olivier, and Anne-Lise Haenni

Subjects
Appropriate anti-herpes therapy, Parsonage-Turner syndrome, Neuralgic amyotrophy, Bilateral phrenic paralysis, Neurotropic herpes virus occurrences, Neurology. Diseases of the nervous system, RC346-429
Abstract

In 2012, a 50 year-old athletic male presented with weakness, pain and unilateral phrenic paralysis, followed by bilateral phrenic paralysis with deep dyspnea. In 2013, the Parsonage-Turner syndrome was diagnosed. When the patient was seen in September 2014 for the first time, he was facing phrenic neuromuscular failure, which led to the hypothesis of neurotropic herpes viruses. A control of the global serological anti-Herpes immunity to analyze his antibody (Ab) levels confirmed herpes immune genetic deficiency. An appropriate herpes chemotherapy treatment was proposed. Immediately, a spectacular recovery of the patient was observed, and after a few weeks, the respiratory function tests showed normal values. The hypothesis of the inductive role of viruses of the herpes family in the Parsonage-Turner syndrome was thus substantiated. The patient's immune deficiency covers the HSV2, HHV3, HHV4, HHV5 and HHV6 Ab levels. This led to the control of herpes in the family lineage: indeed, his daughter presented alterations of her serological herpes Ab levels.

Published
2015
Full Text
View/download PDF

4. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

Author

Sesques, Pierre, Kirkwood, Amy A., Kwon, Mi, Rejeski, Kai, Jain, Michael D., Di Blasi, Roberta, Brisou, Gabriel, Gros, François-Xavier, le Bras, Fabien, Bories, Pierre, Choquet, Sylvain, Rubio, Marie-Thérèse, Iacoboni, Gloria, O’Reilly, Maeve, Casasnovas, René-Olivier, Bay, Jacques-Olivier, Mohty, Mohamad, Joris, Magalie, Abraham, Julie, Castilla Llorente, Cristina, Loschi, Mickael, Carras, Sylvain, Chauchet, Adrien, La Rochelle, Laurianne Drieu, Hermine, Olivier, Guidez, Stéphanie, Cony-Makhoul, Pascale, Fogarty, Patrick, Le Gouill, Steven, Morschhauser, Franck, Gastinne, Thomas, Cartron, Guillaume, Subklewe, Marion, Locke, Frederick L., Sanderson, Robin, Barba, Pere, Houot, Roch, and Bachy, Emmanuel

Published
2024
Full Text
View/download PDF

5. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Author

Dupuis, Jehan, Bachy, Emmanuel, Morschhauser, Franck, Cartron, Guillaume, Fukuhara, Noriko, Daguindau, Nicolas, Casasnovas, René-Olivier, Snauwaert, Sylvia, Gressin, Remy, Fox, Christopher P, d’Amore, Francesco Annibale, Staber, Philipp B, Tournilhac, Olivier, Bouabdallah, Krimo, Thieblemont, Catherine, André, Marc, Rai, Shinya, Ennishi, Daisuke, Gkasiamis, Argyrios, Nishio, Mitsufumi, Fornecker, Luc-Matthieu, Delfau-Larue, Marie-Helene, Sako, Nouhoum, Mule, Sebastien, de Leval, Laurence, Gaulard, Philippe, Tsukasaki, Kunihiro, and Lemonnier, François

Published
2024
Full Text
View/download PDF

7. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Author

Lemoine, Jean, Bachy, Emmanuel, Cartron, Guillaume, Beauvais, David, Gastinne, Thomas, Di Blasi, Roberta, Rubio, Marie-Thérèse, Guidez, Stéphanie, Mohty, Mohamad, Casasnovas, Rene-Olivier, Joris, Magalie, Castilla-Llorente, Cristina, Haioun, Corinne, Hermine, Olivier, Loschi, Michael, Carras, Sylvain, Bories, Pierre, Fradon, Tom, Herbaux, Charles, Sesques, Pierre, Le Gouill, Steven, Morschhauser, Franck, Thieblemont, Catherine, and Houot, Roch

Published
2023
Full Text
View/download PDF

8. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Author

Bachy, Emmanuel, Le Gouill, Steven, Di Blasi, Roberta, Sesques, Pierre, Manson, Guillaume, Cartron, Guillaume, Beauvais, David, Roulin, Louise, Gros, François Xavier, Rubio, Marie Thérèse, Bories, Pierre, Bay, Jacques Olivier, Llorente, Cristina Castilla, Choquet, Sylvain, Casasnovas, René-Olivier, Mohty, Mohamad, Guidez, Stéphanie, Joris, Magalie, Loschi, Michaël, Carras, Sylvain, Abraham, Julie, Chauchet, Adrien, Drieu La Rochelle, Laurianne, Deau-Fischer, Bénédicte, Hermine, Olivier, Gastinne, Thomas, Tudesq, Jean Jacques, Gat, Elodie, Broussais, Florence, Thieblemont, Catherine, Houot, Roch, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

10. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S.P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel, and Maerevoet, Marie

Published
2022
Full Text
View/download PDF

11. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study

Author

Costes-Tertrais, Domitille, Hueso, Thomas, Gastinne, Thomas, Thieblemont, Catherine, Oberic, Lucie, Bouabdallah, Krimo, Garciaz, Sylvain, Tchernonog, Emmanuelle, Dartigeas, Caroline, Ribrag, Vincent, Fogarty, Patrick, Casasnovas, René-Olivier, Houot, Roch, Delette, Caroline, Malak, Sandra, Fornecker, Luc-Matthieu, Gressin, Remy, Damaj, Gandhi, and Le Gouill, Steven

Published
2022
Full Text
View/download PDF

13. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

14. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Author

Kurtz, David M., Soo, Joanne, Co Ting Keh, Lyron, Alig, Stefan, Chabon, Jacob J., Sworder, Brian J., Schultz, Andre, Jin, Michael C., Scherer, Florian, Garofalo, Andrea, Macaulay, Charles W., Hamilton, Emily G., Chen, Binbin, Olsen, Mari, Schroers-Martin, Joseph G., Craig, Alexander F. M., Moding, Everett J., Esfahani, Mohammad S., Liu, Chih Long, Dührsen, Ulrich, Hüttmann, Andreas, Casasnovas, René-Olivier, Westin, Jason R., Roschewski, Mark, Wilson, Wyndham H., Gaidano, Gianluca, Rossi, Davide, Diehn, Maximilian, and Alizadeh, Ash A.

Published
2021
Full Text
View/download PDF

15. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

17. Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Author

Bernard, Sophie, Ghesquieres, Herve, Casasnovas, Rene-Olivier, Griolet, Samuel, Gomes da Silva, Maria, Feugier, Pierre, Morschhauser, Franck, Trotman, Judith, Renaud, Loic, Greil, Richard, García-Sancho, Alejandro Martín, Grosicki, Sebastian, van Eygen, Koen, Copie-Bergman, Christiane, Haioun, Corinne, and Thieblemont, Catherine

Published
2021
Full Text
View/download PDF

18. The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA

Author

Buedts, Lieselot, Wlodarska, Iwona, Finalet-Ferreiro, Julio, Gheysens, Olivier, Dehaspe, Luc, Tousseyn, Thomas, Fornecker, Luc-Matthieu, Lazarovici, Julien, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Kamal, Copie-Bergman, Christiane, Fabiani, Bettina, Dierickx, Daan, Marcelis, Lukas, Vermeesch, Joris, André, Marc, and Vandenberghe, Peter

Published
2021
Full Text
View/download PDF

20. Treatment Strategies in Advanced-Stage Hodgkin Lymphoma.

Author

Dann, Eldad J. and Casasnovas, René-Olivier

Subjects
*MEDICAL protocols, *VINBLASTINE, *ANTINEOPLASTIC agents, *DECISION making in clinical medicine, *POSITRON emission tomography computed tomography, *PREDNISONE, *BLEOMYCIN, *ETOPOSIDE, *VINCRISTINE, *MONOCLONAL antibodies, *DOXORUBICIN, *DACARBAZINE, *PROGRAMMED cell death 1 receptors, *HODGKIN'S disease, *CYCLOPHOSPHAMIDE
Abstract

Simple Summary: The treatment of advanced-stage Hodgkin lymphoma (HL) is a rapidly evolving field with the introduction of new antibody-mediated drugs to first-line therapies and improving progression-free survival (PFS) to 80–94%. The novel modalities include the anti-CD30 antibody drug conjugate brentuximab vedotin and the anti-PD1 antibody (immune checkpoint inhibitor) that blocks a receptor, helping HL cells to turn off the immune cells, fighting malignant cells. When aggressive therapy is used, a negative result of the interim PET/CT scan can be predictive of a favorable outcome, allowing for a subsequent de-escalation of therapy. A more aggressive therapy is associated with higher short-term and long-term toxicity. Thus, the treatment choice for young patients (median age 30–34 years) should also take into consideration the long-term toxicity, since their expected life longevity exceeds half a century. The current review analyzes the recently published studies that may become practice changing and lead to significantly improved PFS. The last 3 decades have witnessed a major evolution in the treatment of advanced-stage Hodgkin lymphoma (HL). The most prominent of these developments include the introduction of the international prognostic scoring (IPS) system; therapeutic decision-making based on both IPS and interim PET/CT data; the finding that a negative interim PET/CT result could be safely used for treatment de-escalation; the introduction of intensive combination chemotherapy like escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin (vincristine), procarbazine, and prednisone); and further modification of this protocol with the incorporation of a conjugated anti-CD30 antibody brentuximab vedotin (BV) into first-line regimens, like BV-AVD (BV+ adriamycin, vinblastine and dacarbazine) and BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone). The accruing data about the toxicity of the escalated BEACOPP protocol have led to decreasing the number of therapeutic cycles, substitution of toxic agents like procarbazine with dacarbazine (e.g., BEACOPDac), and reduction/omission of radiation therapy. Lately, a significant advancement has been made by the integration of checkpoint inhibitors in the first-line treatment, with preliminary results demonstrating the superiority of anti-PD1 combined with chemotherapy (nivolumab-AVD) compared to the BV-AVD regimen. This review aims to analyze recently published studies whose findings could change the treatment practice in advanced-stage HL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Prognostic Value of18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study

Author

Carlier, Thomas, primary, Frécon, Gauthier, additional, Mateus, Diana, additional, Rizkallah, Mira, additional, Kraeber-Bodéré, Françoise, additional, Kanoun, Salim, additional, Blanc-Durand, Paul, additional, Itti, Emmanuel, additional, Gouill, Steven Le, additional, Casasnovas, René-Olivier, additional, Bodet-Milin, Caroline, additional, and Bailly, Clément, additional

Published
2023
Full Text
View/download PDF

22. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Author

Hueso, Thomas, Gastinne, Thomas, Garciaz, Sylvain, Tchernonog, Emmanuelle, Delette, Caroline, Casasnovas, René-Olivier, Durot, Eric, Houot, Roch, Tessoulin, Benoît, Tournilhac, Olivier, Malak, Sandra, Gyan, Emmanuel, Fornecker, Luc-Matthieu, Abraham, Julie, Delapierre, Baptiste, Peyrade, Frédéric, Lemal, Richard, Gressin, Rémy, Chantepie, Sylvain, Borel, Cécile, Morello, Rémy, Bouabdallah, Krimo, Ibrahim, Ahmad, Bouabdallah, Reda, Le Gouill, Steven, and Damaj, Gandhi

Published
2020
Full Text
View/download PDF

24. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

Author

Früh, Martin, Betticher, Daniel C., Stupp, Roger, Xyrafas, Alexandros, Peters, Solange, Ris, Hans Beat, Mirimanoff, Rene Olivier, Ochsenbein, Adrian F., Schmid, Ralph, Matzinger, Oscar, Stahel, Rolf A., Weder, Walter, Guckenberger, Matthias, Rothschild, Sacha I., Lardinois, Didier, Mach, Nicholas, Mark, Michael, Gautschi, Oliver, Thierstein, Sandra, Biaggi Rudolf, Christine, and Pless, Miklos

Published
2019
Full Text
View/download PDF

25. Validation of the ΔSUVmaxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial

Author

Itti, Emmanuel, primary, Blanc-Durand, Paul, additional, Berriolo-Riedinger, Alina, additional, Kanoun, Salim, additional, Kraeber-Bodéré, Françoise, additional, Meignan, Michel, additional, Gat, Elodie, additional, Gouill, Steven Le, additional, Casasnovas, René-Olivier, additional, and Bodet-Milin, Caroline, additional

Published
2023
Full Text
View/download PDF

27. HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Author

Carlo-Stella, Carmelo, Ansell, Stephen, Zinzani, Pier Luigi, Radford, John, Maddocks, Kami, Pinto, Antonio, Collins, Graham P., Bachanova, Veronika, Bartlett, Nancy, Bence-Bruckler, Isabelle, Hamadani, Mehdi, Kline, Justin, Mayer, Jiri, Savage, Kerry J., Advani, Ranjana, Calmi, Paolo, Casasnovas, René-Olivier, Feldman, Tatyana, Hess, Brian, Bastos-Oreiro, Mariana, Iyengar, Sunil, Eisen, Sandy, Negievich, Yanina, Wang, Luqiang, Wuerthner, Jens, and Herrera, Alex F.

Published
2022
Full Text
View/download PDF

28. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH)

Author

Fornecker, Luc-Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, LYSA-FIL-EORTC Intergroup, Hematology, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Adult, Brentuximab Vedotin, Cancer Research, Adolescent, Middle Aged, Vinblastine, Hodgkin Disease, Dacarbazine, Hodgkin lymphoma, brentuximab vedotin, Young Adult, Bleomycin, Treatment Outcome, Oncology, SDG 3 - Good Health and Well-being, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Staging
Abstract

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979 ). METHODS BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023

29. Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections

Author

Rao, Srinivasa P. S., primary, Gould, Matthew K., additional, Noeske, Jonas, additional, Saldivia, Manuel, additional, Jumani, Rajiv S., additional, Ng, Pearly S., additional, René, Olivier, additional, Chen, Yen-Liang, additional, Kaiser, Marcel, additional, Ritchie, Ryan, additional, Francisco, Amanda Fortes, additional, Johnson, Nila, additional, Patra, Debjani, additional, Cheung, Harry, additional, Deniston, Colin, additional, Schenk, Andreas D., additional, Cortopassi, Wilian A., additional, Schmidt, Remo S., additional, Wiedemar, Natalie, additional, Thomas, Bryanna, additional, Palkar, Rima, additional, Ghafar, Nahdiyah A., additional, Manoharan, Vanessa, additional, Luu, Catherine, additional, Gable, Jonathan E., additional, Wan, Kah Fei, additional, Myburgh, Elmarie, additional, Mottram, Jeremy C., additional, Barnes, Whitney, additional, Walker, John, additional, Wartchow, Charles, additional, Aziz, Natasha, additional, Osborne, Colin, additional, Wagner, Juergen, additional, Sarko, Christopher, additional, Kelly, John M., additional, Manjunatha, Ujjini H., additional, Mäser, Pascal, additional, Jiricek, Jan, additional, Lakshminarayana, Suresh B., additional, Barrett, Michael P., additional, and Diagana, Thierry T., additional

Published
2023
Full Text
View/download PDF

32. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Author

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, François Xavier Gros, Marie Thérèse Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, René-Olivier Casasnovas, Mohamad Mohty, Stéphanie Guidez, Magalie Joris, Michaël Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Bénédicte Deau-Fischer, Olivier Hermine, Thomas Gastinne, Jean Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thieblemont, Roch Houot, Franck Morschhauser, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, CHU Lille, Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], and Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Subjects
Biological Products, Receptors, Chimeric Antigen, T-Lymphocytes, [SDV]Life Sciences [q-bio], Antigens, CD19, Clinical Studies as Topic, Humans, Lymphoma, Large B-Cell, Diffuse, General Medicine, Cytokine Release Syndrome, Immunotherapy, Adoptive, General Biochemistry, Genetics and Molecular Biology, Retrospective Studies
Abstract

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.

Published
2022

38. Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Author

Anne Ségolène Cottereau, Louis Rebaud, Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haioun, Loic Ysebaert, Nancy L. Bartlett, Hervé Tilly, René-Olivier Casasnovas, Romain Ricci, Cedric Portugues, Irène Buvat, Michel Meignan, and Franck Morschhauser

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

39. Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry

Author

Federico Erbella, Emmanuel Bachy, Guillaume Cartron, Elodie Gat, Franck Morschhauser, Benoit Tessoulin, Olivier Tournilhac, Choquet Sylvain, François-Xavier Gros, Cristina Castilla-Llorente, Arnaud Campidelli, René-Olivier Casasnovas, Louise Roulin, Pierre Bories, Mohamad Mohty, Martin Carre, Steven Le Gouill, Roch Houot, and Roberta Di Blasi

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

40. Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Author

Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Thomas Gastinne, Marie Thérèse Rubio, Xavier Leleu, Mohamad Mohty, René-Olivier Casasnovas, Magalie Joris, Cristina Castilla-LLorente, Corinne Haioun, Olivier Hermine, Michael Loschi, Sylvain Carras, Pierre Bories, Tom Fradon, Charles Herbaux, Pierre Sesques, Steven Le Gouill, Franck Morschhauser, Catherine Thieblemont, and Roch Houot

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

41. Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab

Author

Rodier, Cyrielle, primary, Kanagaratnam, Lukshe, additional, Morland, David, additional, Herbin, Adélie, additional, Durand, Amandine, additional, Chauchet, Adrien, additional, Choquet, Sylvain, additional, Colin, Philippe, additional, Casasnovas, René Olivier, additional, Deconinck, Eric, additional, Godard, François, additional, Delmer, Alain, additional, Rossi, Cédric, additional, and Durot, Eric, additional

Published
2023
Full Text
View/download PDF

42. Data from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 4 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 7 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure Legend from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 1 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 8 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 5 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 6 from Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy

Author

Kuonen, François, primary, Laurent, Julien, primary, Secondini, Chiara, primary, Lorusso, Girieca, primary, Stehle, Jean-Christophe, primary, Rausch, Thierry, primary, Faes-van't Hull, Eveline, primary, Bieler, Grégory, primary, Alghisi, Gian-Carlo, primary, Schwendener, Reto, primary, Andrejevic-Blant, Snezana, primary, Mirimanoff, René-Olivier, primary, and Rüegg, Curzio, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results